期刊
JOURNAL OF MEDICINAL CHEMISTRY
卷 59, 期 20, 页码 9381-9389出版社
AMER CHEMICAL SOC
DOI: 10.1021/acs.jmedchem.6b00938
关键词
-
资金
- Natural Sciences and Engineering Research Council of Canada (NSERC)
- Ontario Institute for Cancer Research (OICR) [P.SI.015.8]
- Canadian Cancer Society (CCS) [703857]
A high yield synthesis of a novel, small molecule, bisphosphonate-modified trans-cyclooctene (TCO-BP, 2) that binds to regions of active bone metabolism and captures functionalized tetrazines in vivo, via the bioorthogonal inverse electron demand Diels-Alder (IEDDA) cycloaddition, was developed. A Tc-99m-labeled derivative of 2 demonstrated selective localization to shoulder and knee joints in a biodistribution study in normal mice. Compound 2 reacted rapidly with a Lu-177-labeled tetrazine in vitro, and pretargeting experiments in mice, using 2 and the Lu-177-labeled tetrazine, yielded high activity concentrations in shoulder and knee joints, with minimal uptake in other tissues. Pretargeting experiments with 2 and a novel Tc-99m-labeled tetrazine also produced high activity concentrations in the knees and shoulders. Critically, both radiolabeled tetrazines showed negligible uptake in the skeleton and joints when administered in the absence of 2. Compound 2 can be utilized to target functionalized tetrazines to bone and represents a convenient reagent to test novel tetrazines for use with in vivo bioorthogonal pretargeting strategies.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据